Adma Biologics (ADMA) Liabilities and Shareholders Equity (2011 - 2025)

Adma Biologics has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $624.2 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 27.74% year-over-year to $624.2 million; the trailing twelve-month figure through Dec 2025 stood at $2.3 billion (up 40.79% YoY), and the FY2025 full-year result was $624.2 million, up 27.74% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $624.2 million, up from $568.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $624.2 million in Q4 2025, with the low at $232.8 million in Q2 2021.
• Historically, Liabilities and Shareholders Equity has averaged $373.4 million across 5 years, with a median of $345.7 million in 2022.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity declined 5.53% — and 2024, when it surged 48.45%.
• Adma Biologics' Liabilities and Shareholders Equity stood at $276.3 million in 2021, then gained by 26.14% to $348.5 million in 2022, then decreased by 5.53% to $329.2 million in 2023, then jumped by 48.45% to $488.7 million in 2024, then climbed by 27.74% to $624.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $624.2 million (Q4 2025), $568.7 million (Q3 2025), and $558.4 million (Q2 2025), per Business Quant data.